1 min read
Add as a preferred source on Google

Pfizer Announces Starna CAR-T Licensing Deal Worth Up to $2.6 Billion

The exclusive agreement covers development and commercialization of chimeric antigen receptor T-cell therapies.

A sealed cell culture flask sits on a vermilion laboratory surface / TokenPost.ai (mono)
A sealed cell culture flask sits on a vermilion laboratory surface / TokenPost.ai (mono)

Pfizer announced Wednesday an exclusive CAR-T licensing deal with Starna Therapeutics valued at up to $2.6 billion, linking the New York-based drugmaker with a China-based RNA medicines company.

The agreement covers development and commercialization of chimeric antigen receptor T-cell therapies, also known as CAR-T therapies.

Starna Therapeutics is based in China. Pfizer is based in New York.

John Kim

John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.

Loading…